aTYR PHARMA INC (ATYR)

0.97 -0.01 (-1.32%)

As of 2026-02-17 23:55:48 EST

aTyr Pharma is a public biotherapeutics company (Nasdaq: LIFE) that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases. The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 (NRP2) that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease (ILD), a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients.

Traded asNasdaq: ATYR
ISINUS0021202025
CIK0001339970
LEI529900ENQUXMC5EBKO36
EIN203435077
SectorBiotechnology
IndustryBiological Products, (No Diagnostic Substances)
CEOSanjay S Shukla
Employees55
Fiscal Year End1231
Address10240 SORRENTO VALLEY ROAD, SAN DIEGO, CA, 92121
Phone8587318389
Websitehttp://atyrpharma.com
Stock Quotes
trading_symbolregistrant_nametimepricechangepercentage_change
ATYRaTYR PHARMA INC2026-02-17 23:55:480.97-0.01-1.32
This is a preview of the latest data. Subscribe to access the full data.
Company Information
trading_symbolcentral_index_keyregistrant_nameisin_numberlei_numberein_numberexchangesic_codesic_descriptionfiscal_year_endstate_of_incorporationaddress_streetaddress_cityaddress_stateaddress_zip_codeaddress_countryaddress_country_codephone_numbermailing_addressbusiness_addressformer_nameindustryfounding_datechief_executive_officernumber_of_employeeswebsitemarket_capshares_issuedshares_outstandingdescriptionupdate_time
ATYR0001339970aTYR PHARMA INCUS0021202025529900ENQUXMC5EBKO36203435077Nasdaq2836Biological Products, (No Diagnostic Substances)1231DE10240 SORRENTO VALLEY ROADSAN DIEGOCA92121UNITED STATESUS858731838910240 SORRENTO VALLEY ROAD, SAN DIEGO, CA, 9212110240 SORRENTO VALLEY ROAD, SAN DIEGO, CA, 92121—Biotechnology2005Sanjay S Shukla55http://atyrpharma.com116,242,72997,986,63497,986,634aTyr Pharma is a public biotherapeutics company (Nasdaq: LIFE) that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases. The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 (NRP2) that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease (ILD), a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients.2026-02-12 20:20:20
This is a preview of the latest data. Subscribe to access the full data.
ATYR Stock Price (End-of-Day)
This is a preview of the latest data. Subscribe to access the full data.
ATYR Stock Price (1-Minute)
This is a preview of the latest data. Subscribe to access the full data.
Market Cap
Fiscal YearMarket CapChange In Market CapPercentage Change In Market CapShares OutstandingChange In Shares OutstandingPercentage Change In Shares Outstanding
2024116,242,729-4,531,687-3.752288,858,61221,108,58831.1566
2023120,774,41643,580,30956.455567,750,02414,587,97227.4406
202277,194,107991,2541.300853,162,05225,366,25891.2593
This is a preview of the latest data. Subscribe to access the full data.
Executive Compensation
Executive NameExecutive PositionFiscal YearSalaryBonusStock AwardsIncentive Plan CompensationOther CompensationTotal Compensation
Nancy E. DenyesGeneral Counsel2024410,517——139,57618,772729,305
Sanjay S. ShuklaCEO, President2024580,887——246,87710,9981,480,522
Jill M. BroadfootChief Financial Officer2024428,899——145,82610,998746,163
Jill M. BroadfootChief Financial Officer2023414,395——116,03114,327677,837
Sanjay S. ShuklaCEO, President2023561,243——196,43510,5061,300,525
This is a preview of the latest data. Subscribe to access the full data.
Employee Count
Fiscal YearEmployee Count
202459
202359
202270
This is a preview of the latest data. Subscribe to access the full data.
Income Statements
Fiscal Year202420232022
Revenue235,000353,00010,386,000
Cost Of Revenue———
Gross Profit———
Research And Development Expenses54,372,00042,293,00042,808,000
General And Administrative Expenses13,777,00012,979,00013,982,000
Operating Expenses68,149,00055,272,00056,790,000
Operating Income-67,914,000-54,919,000-46,404,000
Net Income-64,023,000-50,389,000-45,338,000
Earnings Per Share Basic-0.86-0.94-1.6
Earnings Per Share Diluted-0.86-0.94-1.6
Weighted Average Shares Outstanding Basic74,261,26553,606,48828,419,569
Weighted Average Shares Outstanding Diluted74,261,26553,606,48828,419,569
This is a preview of the latest data. Subscribe to access the full data.
Balance Sheet Statements
Fiscal Year202420232022
Cash And Cash Equivalents11,055,00022,544,0009,981,000
Marketable Securities Current61,070,00075,622,00056,165,000
Accounts Receivable———
Inventories———
Non Trade Receivables———
Other Assets Current8,093,0002,390,0002,950,000
Total Assets Current81,954,000102,992,00080,871,000
Marketable Securities Non Current———
Property Plant And Equipment4,850,0005,531,0003,059,000
Other Assets Non Current66,000131,000193,000
Total Assets Non Current14,876,00017,661,00014,915,000
Total Assets96,830,000120,653,00095,786,000
Accounts Payable4,323,0003,529,0003,106,000
Deferred Revenue———
Short Term Debt———
Other Liabilities Current9,392,00011,559,0009,862,000
Total Liabilities Current14,967,00016,416,00013,862,000
Long Term Debt———
Other Liabilities Non Current———
Total Liabilities Non Current———
Total Liabilities———
Common Stock84,00063,00029,000
Retained Earnings-532,046,000-468,023,000-417,634,000
Accumulated Other Comprehensive Income-40,000-74,000-433,000
Total Shareholders Equity70,019,00090,658,00071,464,000
This is a preview of the latest data. Subscribe to access the full data.
Cash Flow Statements
Fiscal Year202420232022
Depreciation And Amortization708,000592,000232,000
Share Based Compensation Expense———
Other Non Cash Income Expense3,0006,00092,000
Change In Accounts Receivable———
Change In Inventories———
Change In Non Trade Receivables-402,000-9,054,00011,923,000
Change In Other Assets———
Change In Accounts Payable-1,339,0003,262,0006,741,000
Change In Other Liabilities———
Cash From Operating Activities-69,119,000-33,221,000-41,886,000
Purchases Of Marketable Securities69,103,000106,977,00042,118,000
Sales Of Marketable Securities86,394,00091,050,00090,825,000
Acquisition Of Property Plant And Equipment65,0004,215,0001,641,000
Acquisition Of Business———
Other Investing Activities———
Cash From Investing Activities17,233,000-20,127,00047,245,000
Tax Withholding For Share Based Compensation———
Payments Of Dividends———
Issuance Of Common Stock40,300,00018,400,0004,000,000
Repurchase Of Common Stock———
Issuance Of Long Term Debt———
Repayment Of Long Term Debt———
Other Financing Activities001,000
Cash From Financing Activities39,864,00066,230,0005,451,000
Change In Cash-12,022,00012,882,00010,810,000
Cash At End Of Period11,055,00022,544,0009,981,000
Income Taxes Paid———
Interest Paid137,000172,00054,000
This is a preview of the latest data. Subscribe to access the full data.
Key Metrics
Fiscal Year202420232022
Earnings Per Share-0.86-0.94-1.6
Price To Earnings Ratio-4.2093-1.5-1.3687
Earnings Growth Rate-8.5106-41.25—
Price Earnings To Growth Ratio0.49460.0364—
Book Value Per Share1.10241.94452.8827
Price To Book Ratio3.28380.72510.7597
Ebitda-63,315,000-49,797,000-45,106,000
Enterprise Value———
Dividend Yield———
Dividend Payout Ratio———
Debt To Equity Ratio———
Capital Expenditures27,0003,064,0002,748,000
Free Cash Flow-69,146,000-36,285,000-44,634,000
Return On Equity-0.9144-0.5558-0.6344
One Year Beta0.72670.78420.8546
Three Year Beta0.82220.83750.815
Five Year Beta0.80220.83720.8285
This is a preview of the latest data. Subscribe to access the full data.
Insider Transactions
Insider NameRelationship To IssuerTransaction DateAmount Of SecuritiesAcquired Or DisposedSecurities Owned Following Transaction
DENYES NANCYGeneral Counsel2026-02-041,118D33,124
Broadfoot Jill MarieChief Financial Officer2026-02-041,558D37,296
Shukla SanjayDirector, President and CEO2026-02-043,745D153,553
DENYES NANCYGeneral Counsel2026-02-032,687A34,242
DENYES NANCYGeneral Counsel2026-02-032,687D0
This is a preview of the latest data. Subscribe to access the full data.
Institutional Holdings
Investor NamePeriod Of ReportMarket ValueAmount Of SecuritiesPrice Per Security
ADAR1 Capital Management, LLC2025-12-3139,69150,6850.7831
AQR CAPITAL MANAGEMENT LLC2025-12-31602,847769,8200.7831
CITADEL ADVISORS LLC2025-12-31198,751253,8000.7831
CITADEL ADVISORS LLC2025-12-3199,610127,2000.7831
Dauntless Investment Group, LLC2025-12-3110,96214,0000.783
This is a preview of the latest data. Subscribe to access the full data.
Mutual Fund Holdings
Registrant NamePeriod Of ReportFund NameFund SymbolAmount Of UnitsValue In UsdPercentage Value Compared To Assets
SEI INSTITUTIONAL INVESTMENTS TRUST2025-11-30SIIT Extended Market Index Fund - Class ASMXAX13,00010,146.50.0008
Invesco Exchange-Traded Self-Indexed Fund Trust2025-11-30Invesco Russell 2000(R) Dynamic Multifactor ETFOMFS3,3532,617.020.001
PROSHARES TRUST2025-11-30ProShares Hedge Replication ETFHDG11186.640.0004
PROSHARES TRUST2025-11-30ProShares UltraPro Russell2000URTY6,7695,283.20.0014
PROSHARES TRUST2025-11-30ProShares Ultra Russell2000UWM5,3324,161.630.0017
This is a preview of the latest data. Subscribe to access the full data.